Pharmacokinetics of Haloperidol

@article{Kudo1999PharmacokineticsOH,
  title={Pharmacokinetics of Haloperidol},
  author={S. Kudo and T. Ishizaki},
  journal={Clinical Pharmacokinetics},
  year={1999},
  volume={37},
  pages={435-456}
}
  • S. Kudo, T. Ishizaki
  • Published 1999
  • Medicine
  • Clinical Pharmacokinetics
  • AbstractHaloperidol is commonly used in the therapy of patients with acute and chronic schizophrenia. The enzymes involved in the biotransformation of haloperidol include cytochrome P450 (CYP), carbonyl reductase and uridine diphosphoglucose glucuronosyltransferase.The greatest proportion of the intrinsic hepatic clearance of haloperidol is by glucuronidation, followed by the reduction of haloperidol to reduced haloperidol and by CYP-mediated oxidation. In studies of CYP-mediated disposition in… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 201 REFERENCES
    Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
    • 103
    Pharmacokinetics of Haloperidol
    • 117